TX-FLUENCE
9.6.2021 13:02:11 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its implementations with two major cannabis cultivators in Israel, Springs Valley Cannabis LTD and UNIVO Pharmaceuticals (UNIVO), through Fluence’s ongoing partnership with REMY LTD (REMY), a leading, Israel-based horticultural lighting provider to the country’s growing agriculture industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005120/en/
Following the legalization of medical cannabis in 1993, Israel’s cannabis industry has flourished through in-depth research into efficient production and cultivation processes. With nearly 30 cultivators actively producing medical cannabis and dozens in planning stages, Israel is poised to meet and exceed demand for the estimated 100,000 medical cannabis users throughout the country. As legislation to legalize recreational cannabis use is evaluated, experts predict the industry will maintain its exponential growth trajectory.
“The rapid growth of the medical cannabis industry in Israel is a clear indicator of the recreational market’s potential,” said Timo Bongartz, general manager for Europe, the Middle East and Africa (EMEA) at Fluence. “To maintain the industry’s pace, cultivators must examine and invest in highly efficient production methods that yield consistent, high-quality cannabis products. Lighting plays one of the most crucial roles in that production process.”
Optimal lighting strategies for every phase of the cultivation value chain
Whether seed and variety breeding, cloning and growing plants, or the final cultivation of dense and full buds, each phase of the cannabis value chain requires optimized, curated lighting conditions. Fluence not only offers the industry’s leading LED lighting solutions, but provides evidence-based best practices to identify, implement and maintain the optimal lighting strategy at each phase of cannabis growth. Fluence’s research-backed cultivation methods supported by its team of horticulture specialists enable cannabis cultivators to achieve high-quality, consistent crops while conserving heating, ventilation and air conditioning costs.
REMY echoes Fluence’s cultivation philosophy and approach. Through their partnership, Fluence and REMY are serving Israel’s most innovative cultivators. Springs Valley Cannabis, located in Northern Israel, relies on Fluence’s LED technology in its large-scale, high-end indoor growing facility to ensure superior cannabis flowering within the company’s first cultivation environment.
“Lighting has a major effect on our high-end indoor farm's success,” said Yair Shaked, CEO at Springs Valley Cannabis. “We searched for a lighting partner that would support us and add value for the long run—that's why we chose to work with REMY and Fluence.”
UNIVO, a vertically integrated medical cannabis company covering all aspects of cultivation, manufacturing and distribution, leverages Fluence’s solutions in different stages of the growth cycle, including nursery, vegetative, flowering, mother stock, and research and development, where UNIVO clones and grows cannabis plants.
“Amit farm by UNIVO is one of the most sophisticated and technological farms in the Israeli cannabis industry, and after carefully reviewing the market, we decided to cooperate with Fluence to achieve the best premium cannabis flowers,” added Golan Bitton, CEO at UNIVO.
Continuous investment in new knowledge
“Amid Israel’s revered, dynamic high-tech industry, Fluence’s LED lighting technology is recognized as truly innovative. To maintain that position, we continuously invest in new knowledge and develop new techniques to best serve the world’s cultivators,” Bongartz added.
Fluence works closely with leading research institutions such as Wageningen University & Research to uncover new cultivation strategies and explore the influence of various light spectra on cannabis growth and development. Fluence’s collaborative research insights inform product innovations and provide growers with effective best practices to optimize plant growth.
“The job doesn’t stop when the light fixtures have been installed,” says Jörg Meyer-Brenken, Fluence’s lead account manager for cannabis in EMEA. “On the contrary, that’s when it starts and that’s where the Fluence and REMY teams add extraordinary value. REMY is a true, reliable partner. Their team combines deep lighting knowledge with years of experience in Israeli agriculture and horticulture, making REMY an ideal partner to help us reach a prominent position in this fast-growing market.”
“The end result for the cultivator is an agronomic lighting fixture, but the path to reach the optimal lighting strategy is driven by years of research and practical knowledge,” said Elad Toby, founder, CTO and chief business development officer for REMY. “There is huge opportunity in bringing Fluence’s groundbreaking knowledge to the Israeli medical cannabis market.”
For more information about Fluence, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
About REMY
Established in 2008, REMY 108 LTD specializes in the planning, installation, supervision and quality assurance of large-scale lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and it has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, it today also provides agronomic lighting training at its showroom and headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005120/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
